Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 5

Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial

, , ,

Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.